ANXA1 and neoplasm: One can envision a personalized treatment scenario in which OSCC patients with moderate/poorly differentiated tumor and low Annexin A1 expression receive TPF induction chemotherapy prior to surgery while those with high Annexin A1 expression, receive surgery to avoid the toxicity from chemotherapeutic agents and the delay of definitive treatment.